Form 4: Akero Therapeutics Director Sells Shares Post-Novo Nordisk Merger

Akero Therapeutics director Seth Loring Harrison disposed of all common stock and options following the company's acquisition by Novo Nordisk, receiving cash and contingent value rights.

Summary

• Reporting Person: Seth Loring Harrison, a Director of Akero Therapeutics, Inc.
• Transaction Date: December 9, 2025, which was the effective time of the merger.
• Event: Disposal of all beneficial ownership in Akero Therapeutics common stock, restricted stock units (RSUs), and stock options due to the merger with Novo Nordisk A/S.
• Merger Details: Akero Therapeutics merged with NN Invest Sub, Inc., a subsidiary of Novo Nordisk A/S, becoming a wholly-owned subsidiary of Novo Nordisk.
• Consideration: Each share of common stock and RSU was converted into the right to receive $54.00 in cash (Closing Consideration) and one Contingent Value Right (CVR) worth $6.00 if a specified milestone is achieved.
• Stock Options: Compensatory options were cancelled and converted into a cash payment equal to the product of the excess of the Closing Consideration ($54.00) over the option's per share exercise price, multiplied by the total number of shares, plus one CVR per share.
• Securities Disposed: 136,301 shares of Common Stock (Directly owned), 148,063 shares of Common Stock (Indirectly owned via Les Pommes, LLC), 9,398 Restricted Stock Units (RSUs), and various stock options totaling 108,000 shares with exercise prices ranging from $8.13 to $50.83.
• Beneficial Ownership Following Transaction: 0 shares of common stock and 0 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is generally positive for the reporting person as they realized significant value from their equity holdings through a merger, receiving a substantial cash payment and potential upside from a CVR. For the company, it marks the successful completion of an acquisition, albeit ending its independent public status.

Positives

• The reporting person received a significant cash payment for their equity holdings due to the merger.
• The merger consideration included a fixed cash component of $54.00 per share, providing immediate liquidity and certainty.
• The inclusion of a Contingent Value Right (CVR) offers potential additional upside of $6.00 per share if a specified milestone is met.
• All restricted stock units (RSUs) and stock options were deemed fully vested and converted into merger consideration, benefiting the reporting person.

Negatives

• Akero Therapeutics, Inc. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Novo Nordisk.
• The reporting person no longer holds any direct or indirect beneficial ownership in Akero Therapeutics common stock or derivative securities.
• The value of the CVR is contingent on a future milestone, introducing an element of uncertainty to the full merger consideration.

Risks

• The $6.00 per share Contingent Value Right (CVR) is dependent on the achievement of a specified milestone, which may or may not occur.

Future Outlook

The future outlook for the former Akero Therapeutics shareholders who received CVRs depends on the achievement of the specified milestone for the $6.00 contingent payment. The company itself is now a wholly-owned subsidiary of Novo Nordisk.

Management Comments

• This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger... effective as of December 9, 2025.
• At the Effective Time, each share of common stock... was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00... and (ii) one contractual contingent value right... representing the right to receive $6.00 in cash, if a specified milestone is achieved.
• Each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right... to receive the Merger Consideration.
• Each compensatory option... whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price... plus one CVR for each share.

Industry Context

This filing reflects a significant consolidation event in the biopharmaceutical industry, where a smaller, innovative company (Akero Therapeutics) focused on metabolic diseases (implied by Novo Nordisk's interest) is acquired by a global pharmaceutical giant (Novo Nordisk). Such acquisitions are common strategies for larger companies to expand their pipeline and market share, while providing an exit for investors in the acquired entity.

Comparison to Industry Standards

• The acquisition of Akero Therapeutics by Novo Nordisk is consistent with a broader industry trend of large pharmaceutical companies acquiring smaller biotech firms to gain access to promising drug candidates and intellectual property.
• The use of Contingent Value Rights (CVRs) in merger agreements is a common mechanism in the biotech and pharmaceutical sectors, allowing acquirers to mitigate risk by tying a portion of the acquisition price to the successful achievement of clinical or regulatory milestones, similar to deals like Sanofi's acquisition of Principia Biopharma or Bristol Myers Squibb's acquisition of Celgene (which also included CVRs).
• The valuation implied by the $54.00 cash plus $6.00 CVR per share would be assessed against comparable M&A transactions in the metabolic disease or NASH space, considering Akero's clinical stage assets (e.g., efruxifermin for NASH).

Management Changes

Corporate Governance

Related Party Transactions

• The filing notes that 148,063 shares were held indirectly by Les Pommes, LLC, a family limited liability company for which the Reporting Person is the manager. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders (pre-merger): Received $54.00 cash per share and one CVR potentially worth $6.00, providing a clear exit and return on investment.
• Employees: While not explicitly detailed, employees holding stock options and RSUs would have seen their equity converted into cash and CVRs, providing liquidity. The company's integration into Novo Nordisk would impact employment structure.
• Customers/Patients: The merger could potentially accelerate or alter the development and commercialization path of Akero's therapeutic candidates under Novo Nordisk's larger resources.

Next Steps

• Monitoring the achievement of the specified milestone for the Contingent Value Right (CVR) to determine if the additional $6.00 per share payment will be made.

Key Dates

Keywords

Akero Therapeutics, Novo Nordisk, Merger, Acquisition, Form 4, Insider Trading, Beneficial Ownership, Contingent Value Right, CVR, Stock Options, Restricted Stock Units, AKRO